Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pneumococcal polysaccharide vaccine response in healthy adults
NL-OMON55592Recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jan 2020
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of 23-valent pneumococcal polysaccharide vaccine in pneumococcal disease, sponsored by St. Antonius Ziekenhuis. Primary endpoint: Serotype-specific IgG antibody titers at 4 weeks. Started Jan 2020; status: recruiting.
02
Drugs
23-valent pneumococcal polysaccharide vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NL-OMON55592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55592.